IL17A and metabolic dysfunction-associated steatotic liver disease: The latter plays an important role in MASLD progression; it has been reported that treatment with anti-IL-17 monoclonal antibody of high-fatty-diet (HFD) mice improved liver function with the attenuation of lipid accumulation.